Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PLSE |
---|---|---|
09:32 ET | 548 | 17.18 |
09:39 ET | 179 | 16.98 |
09:41 ET | 576 | 16.97 |
09:48 ET | 4316 | 16.85 |
09:50 ET | 200 | 16.915 |
09:52 ET | 100 | 16.92 |
09:54 ET | 100 | 16.85 |
09:56 ET | 100 | 16.85 |
09:59 ET | 400 | 16.805 |
10:01 ET | 100 | 16.9 |
10:03 ET | 1800 | 17 |
10:06 ET | 171 | 17 |
10:10 ET | 4993 | 16.81 |
10:12 ET | 3499 | 16.86 |
10:17 ET | 100 | 17.03 |
10:21 ET | 100 | 16.845 |
10:24 ET | 100 | 16.845 |
10:26 ET | 100 | 16.845 |
10:28 ET | 100 | 16.845 |
10:30 ET | 100 | 16.85 |
10:32 ET | 600 | 17 |
10:37 ET | 100 | 17.04 |
10:42 ET | 2086 | 17.11 |
10:44 ET | 200 | 17.16 |
10:46 ET | 105 | 17.21 |
10:51 ET | 300 | 17.26 |
10:53 ET | 200 | 17.18 |
10:55 ET | 100 | 17.1 |
10:57 ET | 200 | 17.11 |
11:00 ET | 100 | 17.09 |
11:02 ET | 200 | 17.085 |
11:04 ET | 100 | 17.08 |
11:06 ET | 263 | 17.05 |
11:09 ET | 100 | 17.03 |
11:11 ET | 200 | 17.14 |
11:13 ET | 100 | 17.04 |
11:15 ET | 100 | 17.04 |
11:18 ET | 200 | 17.14 |
11:20 ET | 100 | 17.04 |
11:24 ET | 1165 | 17.2 |
11:36 ET | 100 | 17.24 |
11:42 ET | 100 | 17.15 |
11:44 ET | 300 | 17.245 |
11:45 ET | 340 | 17.245 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Pulse Biosciences Inc | 1.0B | -21.8x | --- |
Nano-X Imaging Ltd | 356.8M | -6.2x | --- |
Atlantic International Corp | 292.4M | -0.7x | --- |
Simulations Plus Inc | 621.6M | 67.1x | +3.18% |
IRadimed Corp | 626.9M | 34.2x | +21.02% |
Orchestra Biomed Holdings Inc | 182.7M | -3.1x | --- |
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.0B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 61.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.74 |
EPS | $-0.79 |
Book Value | $0.80 |
P/E Ratio | -21.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.